Imagine growing a tiny, simplified version of a human brain in a lab dish that acts like a biological mirror for a specific patient. This project adds a high-tech electronic grid under these mini-brains to listen to their electrical signals in real-time. An AI then translates these complex signals into a clear map, showing exactly how a drug affects the brain without needing a human trial.
Current CNS drug testing relies on animal models or 2D cultures that fail to mimic the human brain's complexity, leading to high clinical trial failure rates. There is a critical lack of predictive, personalized tools for neurotoxicity and neuropsychiatric disease modeling.
A prototype platform combining hiPSC-derived 3D cortical organoids, a 24-well 3D high-density multi-electrode array (HD-MEA), and ML-based data analysis algorithms.
If you are a drug discovery firm dealing with high failure rates in CNS clinical trials — this project developed a bio-digital twin model that allows for precise and predictive drug screening. This reduces risk by validating efficacy on human-like cortical organoids before human testing.
If you are a CRO dealing with the limitations of 2D cell cultures for safety testing — this project developed a 3D multi-electrode array platform that provides high-resolution electrophysiological recordings. This enables more accurate neurotoxicity screening for new chemical entities.
If you are a clinic dealing with the lack of personalized treatment options for neuropsychiatric diseases — this project developed a platform using patient-derived iPSCs to create personalized brain models. This allows doctors to test treatments on a patient's own 'digital twin' first.
Based on available project data, specific commercial pricing is not provided as the project is currently in the prototype development phase.
Yes, the project is developing a 24-well 3D HD-MEA with dimensions specifically designed to be suitable for high-throughput assays.
Based on available project data, the IP status is not explicitly detailed, though the project involves a consortium of three universities and one SME.
The platform integrates 3D cortical organoids with micropillar electrodes and uses automated machine learning algorithms to process large spatiotemporal data sets.
The project period runs from 2023-04-01 to 2028-03-31, suggesting the prototype and validation phases will continue through 2028.
The consortium is research-heavy, consisting of 3 universities and 1 SME across 4 countries (NL, CH, DE, IT). With an industry ratio of 25%, the project is primarily driven by academic expertise from Erasmus MC, but the inclusion of an SME (3Brain) ensures that hardware development for the 24-well MEA plates is aligned with commercial scalability.
Erasmus Universitair Medisch Centrum Rotterdam
Contact us to explore licensing opportunities for the 3D-BrAIn bio-digital twin platform.
